US-based Beckman Coulter, a clinical diagnostics leader, and Scopio Labs, a medtech company based in Israel that develops digital cell morphology workflow solutions, have jointly announced expansion of its long-term partnership to include a global distribution agreement of Scopio's Full-Field Bone Marrow Aspirate (FF-BMA) Application. Scopio's X100 / X100HT with FF-BMA Application are CE-Marked.

Scopio's FF-BMA Application transforms BMA analysis by combining high-resolution Full-Field imaging with a robust AI-powered decision support system into a fully digital workflow seamlessly integrated with Scopio's X100 and X100HT scanners.

It also enables hematopathologists to review bone marrow smears remotely (via a secure hospital network), potentially reducing turnaround time, fostering collaboration, facilitating second opinions, and bolstering diagnostic confidence.

Since 2022, Beckman Coulter and Scopio have been working together to accelerate adoption of the next generation of digital cell morphology. Scopio's X100 and X100HT digital cell morphology platforms employ full-field imaging and AI decision support eliminating the need for manual microscopy, while providing laboratory scientists and physicians true workflow benefits with simple to use remote viewing through a secured network.

In 2023, Beckman Coulter Diagnostics announced a new end-to-end automated hematology solution by connecting its DxH 900 Workcell and DxH Slidemaker Stainer II with the Scopio X100HT high-throughput digital cell morphology platform, complete with digitalised, AI-assisted peripheral blood smear analysis.